FogPharma
A biopharmaceutical company pioneering the discovery and development of Helicon therapeutics, which are small proteins capable of efficient cell-entry and modulating protein-protein interactions.
Through this novel modality, FogPharma aims to address the limitations of existing drug classes and achieve universal druggability. Spun out of Harvard University by Dr Gregory Verdine, FogPharma is advancing a broad pipeline of Helicon therapeutics against important and biologically validated cancer targets that have remained elusive to other approaches, with the goal of providing new targeted treatment options for significant cancer patient populations.
In November 2022, FogPharma completed a $178 million Series D financing and has raised more than $360 million to date from leading life sciences investors.
Latest FogPharma News & Features
2 March 2024
30 March 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze